| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/03/2005 | US20050026977 Controlling dosage; sustained and significant weight loss in an overweight subject |
| 02/03/2005 | US20050026963 Pyrazole substituted directly, or by a bridge, with a heteroaryl group containing N adjacent to the point of connection of the heteroaryl useful in the treatment of psychiatric and mood disorders such as, schizophrenia, anxiety, depression, bipolar disorder, circadian rhythm and sleep disorders |
| 02/03/2005 | US20050026948 Inflammatory and/or obstructive respiratory tract disorders |
| 02/03/2005 | US20050026933 Administering a 3-cyanoquinoline derivative andcapecitabine, paclitaxel, 5-fluorouracil or cisplatin; antitumor and anticarcinogenic agents |
| 02/03/2005 | US20050026927 Pyrazole derivatives as psychopharmaceuticals |
| 02/03/2005 | US20050026909 2-(1-piperazinyl) thieno[2,3-d]pyrimidine derivatives having 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity; nocturia or overactive bladder |
| 02/03/2005 | US20050026902 Combination therapy for treatment of HIV infection as well as HIV associated diseases and related disorders comprising the administration to a subject of an anti-human immunodeficiency virus agent in combination with a cyclooxygenase-2 selective inhibitor |
| 02/03/2005 | US20050026891 Progesterone receptor modulators with increased antigonadotropic activity for female birth control and hormone replacement therapy |
| 02/03/2005 | US20050026890 Such as loratadine, cetirizine, or fexofenadine; low amounts of active agents, less prone to detrimental side effects; reducing levels of, or sensitivity to, adenosine or adenosine receptors |
| 02/03/2005 | US20050026886 Phosphodiesterase IV (PDE IV) inhibitor such as roflumilast or cilomilast with a 1-(3-phenoxypropyl)-3-((2-hydroxy-2,2-bisthien-2-yl)acetoxy)quinuclidinium salt of given formula; kit with dosage forms and instructions; treating inflammatory or obstructive respiratory diseases |
| 02/03/2005 | US20050026885 Administering during follicular phase in a dosage less than an ovulation-inhibiting or abortion-inductive dose; 11 beta -[(4-N,N-Dimethylamino) -phenyl]-17 beta -hydroxy-17 alpha -propinyl-4,9(10)-estradien-3-one (RU 38486) for example; will not abort previously implanted fetus |
| 02/03/2005 | US20050026884 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| 02/03/2005 | US20050026883 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 02/03/2005 | US20050026882 Such as montelukast, zafirlukast or pranlukast; low amounts of active agents, less prone to detrimental side effects |
| 02/03/2005 | US20050026881 Immunoglobulin E (IgE); antibody such as omalizumab; low amounts of active agents, less prone to detrimental side effects |
| 02/03/2005 | US20050026880 Such as cromolyn sodium or nedocromil sodium; low amounts of active agents, less prone to detrimental side effects; reducing levels of, or sensitivity to, adenosine or adenosine receptors |
| 02/03/2005 | US20050026879 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 02/03/2005 | US20050026866 Detecting or treating mammalian tumor cells; tissue-targeted therapy; genetic engineered Bordetella pertussis; biodrugs |
| 02/03/2005 | US20050026858 Modified nucleotides for immunotherapy; induce immunology response; consisting of nucleoside methylphosphonate and 2'-O-methyl-ribonucleoside groups |
| 02/03/2005 | US20050026852 Reducing the toxicity side effect of anticarcinogenic agent, including a selenium compound selecting from seleno-L-methionine or methylselenocysteine; administering before, during or after administration of chemotherapeutic drug |
| 02/03/2005 | US20050026850 Metered dose inhalers; low amounts of active agents, less prone to detrimental side effects |
| 02/03/2005 | US20050026848 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease |
| 02/03/2005 | US20050026842 To separate the brain-derived wanting of the opioid from the analgesic or anti-diarrhea, loose stool effect of the opioid; synergistic; simultaneously not allowing for increased dopamine in regions of the brain that would effect wanting of the opiod |
| 02/03/2005 | US20050026836 mixture of growth factors, enzyme inhibitors and carrier, diluent or excipients; wound healing agents; antiulcer agents; chronic wounds, e.g. decubitus ulcers |
| 02/03/2005 | US20050026835 Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators |
| 02/03/2005 | US20050026824 Method for treating autoimmune diseases and screening method for preventive or therapeutic agent for the same |
| 02/03/2005 | US20050026283 Using electric field modification to transfer components across cell barriers; organelle transfer; in vitro fertility |
| 02/03/2005 | US20050026278 RNA interference mediating small RNA molecules |
| 02/03/2005 | US20050026251 Netrin receptor protein for use in identification of modulator for use in treatment and prevention of infection, nervous system, autoimmune, inflammatory, psycological and reproductive disorders |
| 02/03/2005 | US20050026223 Identifying modulators which bind hormone receptors, enhance bone characteristics and treat bone disorders |
| 02/03/2005 | US20050026220 Isolation and mobilization of stem cells expressing vegfr-1 |
| 02/03/2005 | US20050026214 Method of identifying glycosyl transferase binding compounds |
| 02/03/2005 | US20050026211 Compositions and methods relating to lung specific genes |
| 02/03/2005 | US20050026182 Human CDNAS and proteins and uses thereof |
| 02/03/2005 | US20050025807 Cured porous calcium phosphate material and uses thereof |
| 02/03/2005 | US20050025756 Combination with a solvent, skin buffer and antioxidant to improve solubility and bioavailability for a variety of dosage forms |
| 02/03/2005 | US20050025751 Increased or reduced expression of tumor necrosis factors or interleukins; antiinflammatory agents; autoimmune diseases |
| 02/03/2005 | US20050025748 Delivery of compounds with rehydrated blood cells |
| 02/03/2005 | US20050025734 Lactacystin, a peptidyl aldehyde, or a peptidyl epoxy ketone inhibits proteasomal activity; epidermal growth factor, a fibroblast growth factor, a platelet-derived growth factor, a transforming growth factor, a parathyroid hormone, etc for promoting skin tissue growth, an excipient |
| 02/03/2005 | US20050025718 Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| 02/03/2005 | DE10332473A1 Ambroxol für die Behandlung von Epilepsie Ambroxol for the treatment of epilepsy |
| 02/03/2005 | DE10332472A1 Ambroxol für die Behandlung von Tinnitus Ambroxol for the treatment of tinnitus |
| 02/03/2005 | DE10329908A1 Composition comprising xenon and local anesthetic, useful in regional or local anesthetic procedures |
| 02/03/2005 | CA2536383A1 Nicotinamide compounds useful as pde4 inhibitors |
| 02/03/2005 | CA2536111A1 Oral compositions for treatment of diseases |
| 02/03/2005 | CA2534178A1 Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| 02/03/2005 | CA2533707A1 Treatment of lesions of the soft tissues |
| 02/03/2005 | CA2533649A1 Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
| 02/03/2005 | CA2533117A1 Combinations for the treatment of depression |
| 02/03/2005 | CA2532874A1 Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
| 02/03/2005 | CA2532807A1 Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome |
| 02/03/2005 | CA2532730A1 Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof |
| 02/03/2005 | CA2532400A1 Tyrosine kinase inhibitors |
| 02/03/2005 | CA2529405A1 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| 02/03/2005 | CA2528043A1 Marks as modifiers of the pten pathway and methods of use |
| 02/03/2005 | CA2525829A1 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/03/2005 | CA2523651A1 Antibacterial methods and compositions |
| 02/03/2005 | CA2522338A1 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 02/02/2005 | EP1502962A2 Methods for assessing and treating cancer |
| 02/02/2005 | EP1502604A1 Use of nitric oxide mimetics in cancer treatment |
| 02/02/2005 | EP1502601A1 Use of neurotoxin therapy for treatment of urinary retention |
| 02/02/2005 | EP1502591A2 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 02/02/2005 | EP1502586A1 Preparations for the application of anti-inflammatory agents |
| 02/02/2005 | EP1502109A2 Compositions and methods relating to endothelial cell signaling using the protease activated receptor (par1) |
| 02/02/2005 | EP1501948A1 A dna enzyme to inhibit plasminogen activator inhibitor-1 |
| 02/02/2005 | EP1501930A2 Oligomeric compounds for the modulation hif-1alpha expression |
| 02/02/2005 | EP1501925A2 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
| 02/02/2005 | EP1501918A1 Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| 02/02/2005 | EP1501860A2 Modulation of heat-shock-protein-based immunotherapies |
| 02/02/2005 | EP1501857A2 Novel pancortin-pablo protein interactions and methods of use thereof |
| 02/02/2005 | EP1501855A2 Novel compositions and methods in cancer |
| 02/02/2005 | EP1501852A2 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 02/02/2005 | EP1501830A1 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases |
| 02/02/2005 | EP1501825A2 Substituted imidazolylmethyl pyridine and pyrazine derivatives: gaba a receptor ligands |
| 02/02/2005 | EP1501819A1 Estrogen receptor modulators |
| 02/02/2005 | EP1501813A2 Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them |
| 02/02/2005 | EP1501790A2 Novel sodium channel blockers |
| 02/02/2005 | EP1501605A1 Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency |
| 02/02/2005 | EP1501566A1 Medical products comprising a haemocompatible coating, production and use thereof |
| 02/02/2005 | EP1501565A1 Compounds and method for coating surfaces in a haemocompatible manner |
| 02/02/2005 | EP1501563A1 Carbon nanotubules for storage of nitric oxide |
| 02/02/2005 | EP1501560A1 Surgical material comprising water soluble glass fibres |
| 02/02/2005 | EP1501547A1 Methods and conpositions for treating, preventing or delaying onset of a neoplasm |
| 02/02/2005 | EP1501546A1 Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor |
| 02/02/2005 | EP1501545A2 Use of tnfalpha antibodies and another drug |
| 02/02/2005 | EP1501544A2 Alcam and alcam modulators |
| 02/02/2005 | EP1501535A1 Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents |
| 02/02/2005 | EP1501526A1 Curcumin for the prevention and/or treatment of tissue damage |
| 02/02/2005 | EP1501517A1 Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention |
| 02/02/2005 | EP1501513A2 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
| 02/02/2005 | EP1501511A1 Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway |
| 02/02/2005 | EP1501500A2 Carvedilol formulations |
| 02/02/2005 | EP1501498A1 Pharmaceutical composition comprising a lipase inhibitor and glucomannan |
| 02/02/2005 | EP1501497A2 Catechin multimers as therapeutic drug delivery agents |
| 02/02/2005 | EP1501495A1 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori |
| 02/02/2005 | EP1501491A2 Methods and compositions for treatment of cancer pain |
| 02/02/2005 | EP1501489A1 Combination therapy for the treatment of cancer |
| 02/02/2005 | EP1501488A1 USE OF GABA sb B /sb RECEPTOR POSITIVE MODULATORS IN GASTRO-INSTESTINAL DISORDERS |
| 02/02/2005 | EP1501482A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| 02/02/2005 | EP1501478A1 Warming and nonirritating anhydrous lubricant compositions |